COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
- Autores
- Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; Cayetti, Luis A.; Mirofsky, Matias A.; Boietti, Bruno Rafael; Gómez Huelgas, Ricardo; Casas Rojo, José M.; Antón Santos, Juan M.; Núñez Cortés, Jesús M.; Lumbreras, Carlos; Ramos Rincón, Jose Manuel; Barrio, Noelia G.; Pedrera Jiménez, Miguel; Martin Escalante, María D.; Ruiz, Francisco R.; Onieva García, María Á.; Toso, Carlos R.; Risk, Marcelo; Klén, Riku; Pollán, Javier A.; Gómez Varela, David
- Año de publicación
- 2023
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).
Fil: Huespe, Ivan. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Ferraris, Augusto. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Lalueza, Antonio. 12 de Octubre University Hospital; España
Fil: Valdez, Pascual. Hospital General de Agudos Dalmacio Velez Sarsfield ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Peroni, María Leticia. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Cayetti, Luis A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Mirofsky, Matias A.. Hospital Municipal Doctor Leónidas Lucero; Argentina
Fil: Boietti, Bruno Rafael. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Gómez Huelgas, Ricardo. Universidad de Málaga; España
Fil: Casas Rojo, José M.. Infanta Cristina University Hospital; España
Fil: Antón Santos, Juan M.. Infanta Cristina University Hospital; España
Fil: Núñez Cortés, Jesús M.. Hospital General Universitario Gregorio Marañón (hosp Gral Univ G. Marañón); España
Fil: Lumbreras, Carlos. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Ramos Rincón, Jose Manuel. Universidad de Miguel Hernández; España
Fil: Barrio, Noelia G.. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Pedrera Jiménez, Miguel. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Martin Escalante, María D.. Costa del Sol Hospital; España
Fil: Ruiz, Francisco R.. Costa del Sol Hospital; España
Fil: Onieva García, María Á.. Costa del Sol Hospital; España
Fil: Toso, Carlos R.. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Klén, Riku. University of Turku; Finlandia
Fil: Pollán, Javier A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Gómez Varela, David. Universidad de Viena; Austria - Materia
-
COVID-19
COVID-19 VACCINES
HOSPITALIZATION
OXYGEN THERAPY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/227961
Ver los metadatos del registro completo
id |
CONICETDig_91ab43a4764fe50b6af829c585e3fd78 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/227961 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort studyHuespe, IvanFerraris, AugustoLalueza, AntonioValdez, PascualPeroni, María LeticiaCayetti, Luis A.Mirofsky, Matias A.Boietti, Bruno RafaelGómez Huelgas, RicardoCasas Rojo, José M.Antón Santos, Juan M.Núñez Cortés, Jesús M.Lumbreras, CarlosRamos Rincón, Jose ManuelBarrio, Noelia G.Pedrera Jiménez, MiguelMartin Escalante, María D.Ruiz, Francisco R.Onieva García, María Á.Toso, Carlos R.Risk, MarceloKlén, RikuPollán, Javier A.Gómez Varela, DavidCOVID-19COVID-19 VACCINESHOSPITALIZATIONOXYGEN THERAPYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).Fil: Huespe, Ivan. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Ferraris, Augusto. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Lalueza, Antonio. 12 de Octubre University Hospital; EspañaFil: Valdez, Pascual. Hospital General de Agudos Dalmacio Velez Sarsfield ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Peroni, María Leticia. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Cayetti, Luis A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Mirofsky, Matias A.. Hospital Municipal Doctor Leónidas Lucero; ArgentinaFil: Boietti, Bruno Rafael. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Gómez Huelgas, Ricardo. Universidad de Málaga; EspañaFil: Casas Rojo, José M.. Infanta Cristina University Hospital; EspañaFil: Antón Santos, Juan M.. Infanta Cristina University Hospital; EspañaFil: Núñez Cortés, Jesús M.. Hospital General Universitario Gregorio Marañón (hosp Gral Univ G. Marañón); EspañaFil: Lumbreras, Carlos. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; EspañaFil: Ramos Rincón, Jose Manuel. Universidad de Miguel Hernández; EspañaFil: Barrio, Noelia G.. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; EspañaFil: Pedrera Jiménez, Miguel. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; EspañaFil: Martin Escalante, María D.. Costa del Sol Hospital; EspañaFil: Ruiz, Francisco R.. Costa del Sol Hospital; EspañaFil: Onieva García, María Á.. Costa del Sol Hospital; EspañaFil: Toso, Carlos R.. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Klén, Riku. University of Turku; FinlandiaFil: Pollán, Javier A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Gómez Varela, David. Universidad de Viena; AustriaWiley-liss, div John Wiley & Sons Inc.2023-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/227961Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; et al.; COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 95; 5; 5-2023; 1-100146-6615CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/jmv.28786info:eu-repo/semantics/altIdentifier/doi/10.1002/jmv.28786info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:14:11Zoai:ri.conicet.gov.ar:11336/227961instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:14:11.685CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
title |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
spellingShingle |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study Huespe, Ivan COVID-19 COVID-19 VACCINES HOSPITALIZATION OXYGEN THERAPY |
title_short |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
title_full |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
title_fullStr |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
title_full_unstemmed |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
title_sort |
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study |
dc.creator.none.fl_str_mv |
Huespe, Ivan Ferraris, Augusto Lalueza, Antonio Valdez, Pascual Peroni, María Leticia Cayetti, Luis A. Mirofsky, Matias A. Boietti, Bruno Rafael Gómez Huelgas, Ricardo Casas Rojo, José M. Antón Santos, Juan M. Núñez Cortés, Jesús M. Lumbreras, Carlos Ramos Rincón, Jose Manuel Barrio, Noelia G. Pedrera Jiménez, Miguel Martin Escalante, María D. Ruiz, Francisco R. Onieva García, María Á. Toso, Carlos R. Risk, Marcelo Klén, Riku Pollán, Javier A. Gómez Varela, David |
author |
Huespe, Ivan |
author_facet |
Huespe, Ivan Ferraris, Augusto Lalueza, Antonio Valdez, Pascual Peroni, María Leticia Cayetti, Luis A. Mirofsky, Matias A. Boietti, Bruno Rafael Gómez Huelgas, Ricardo Casas Rojo, José M. Antón Santos, Juan M. Núñez Cortés, Jesús M. Lumbreras, Carlos Ramos Rincón, Jose Manuel Barrio, Noelia G. Pedrera Jiménez, Miguel Martin Escalante, María D. Ruiz, Francisco R. Onieva García, María Á. Toso, Carlos R. Risk, Marcelo Klén, Riku Pollán, Javier A. Gómez Varela, David |
author_role |
author |
author2 |
Ferraris, Augusto Lalueza, Antonio Valdez, Pascual Peroni, María Leticia Cayetti, Luis A. Mirofsky, Matias A. Boietti, Bruno Rafael Gómez Huelgas, Ricardo Casas Rojo, José M. Antón Santos, Juan M. Núñez Cortés, Jesús M. Lumbreras, Carlos Ramos Rincón, Jose Manuel Barrio, Noelia G. Pedrera Jiménez, Miguel Martin Escalante, María D. Ruiz, Francisco R. Onieva García, María Á. Toso, Carlos R. Risk, Marcelo Klén, Riku Pollán, Javier A. Gómez Varela, David |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
COVID-19 COVID-19 VACCINES HOSPITALIZATION OXYGEN THERAPY |
topic |
COVID-19 COVID-19 VACCINES HOSPITALIZATION OXYGEN THERAPY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy). Fil: Huespe, Ivan. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina Fil: Ferraris, Augusto. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina Fil: Lalueza, Antonio. 12 de Octubre University Hospital; España Fil: Valdez, Pascual. Hospital General de Agudos Dalmacio Velez Sarsfield ; Gobierno de la Ciudad Autonoma de Buenos Aires; Fil: Peroni, María Leticia. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina Fil: Cayetti, Luis A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina Fil: Mirofsky, Matias A.. Hospital Municipal Doctor Leónidas Lucero; Argentina Fil: Boietti, Bruno Rafael. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina Fil: Gómez Huelgas, Ricardo. Universidad de Málaga; España Fil: Casas Rojo, José M.. Infanta Cristina University Hospital; España Fil: Antón Santos, Juan M.. Infanta Cristina University Hospital; España Fil: Núñez Cortés, Jesús M.. Hospital General Universitario Gregorio Marañón (hosp Gral Univ G. Marañón); España Fil: Lumbreras, Carlos. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España Fil: Ramos Rincón, Jose Manuel. Universidad de Miguel Hernández; España Fil: Barrio, Noelia G.. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España Fil: Pedrera Jiménez, Miguel. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España Fil: Martin Escalante, María D.. Costa del Sol Hospital; España Fil: Ruiz, Francisco R.. Costa del Sol Hospital; España Fil: Onieva García, María Á.. Costa del Sol Hospital; España Fil: Toso, Carlos R.. Universidad de Buenos Aires. Facultad de Medicina; Argentina Fil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina Fil: Klén, Riku. University of Turku; Finlandia Fil: Pollán, Javier A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina Fil: Gómez Varela, David. Universidad de Viena; Austria |
description |
The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy). |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/227961 Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; et al.; COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 95; 5; 5-2023; 1-10 0146-6615 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/227961 |
identifier_str_mv |
Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; et al.; COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 95; 5; 5-2023; 1-10 0146-6615 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/jmv.28786 info:eu-repo/semantics/altIdentifier/doi/10.1002/jmv.28786 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Wiley-liss, div John Wiley & Sons Inc. |
publisher.none.fl_str_mv |
Wiley-liss, div John Wiley & Sons Inc. |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614066303139840 |
score |
13.070432 |